Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.

@article{Froestl2013CognitiveE,
  title={Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.},
  author={W. Froestl and A. Pfeifer and A. Muhs},
  journal={Journal of Alzheimer's disease : JAD},
  year={2013},
  volume={34 1},
  pages={
          1-114
        }
}
Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed… Expand
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
TLDR
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 18 categories according to their mechanism(s) of action. Expand
Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
TLDR
In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified and enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. Expand
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
TLDR
The present review covers the evolution of research in this field through April 2014 and describes drugs interacting with 60 enzymes versus 43 enzymes in the first paper. Expand
Neurotransmitters and Memory
TLDR
Molecular signaling is key field of scientific investigation; particularly, as the study of the molecular bases of memory has been become a field of the major scientific interest, hence, in the following lines some aspects are mentioned. Expand
Nootropics: Phytochemicals with Neuroprotective and Neurocognitive Enhancing Properties
TLDR
Nootropics open the door for new research, clinical implementation and promotion of integrative health especially in cognitive neuroscience by implementing products of natural sources to improve neurocognitive functioning and health improvement. Expand
A Novel Heterocyclic Compound CE-104 Enhances Spatial Working Memory in the Radial Arm Maze in Rats and Modulates the Dopaminergic System
TLDR
The effects upon cognition of a chemically synthesized novel MAT inhibiting compound 2-(benzhydrylsulfinylmethyl)-4-methylthiazole (named as CE-104) is examined to propose a possible mechanism for the observed learning and memory enhancement in the RAM. Expand
The Psychonauts’ World of Cognitive Enhancers
TLDR
Assessing psychonaut fora/platforms to better understand the online situation regarding CEs shows that NPSfinder® is helpful as part of an Early Warning System, which could update clinicians with the growing numbers of nootropics in the increasingly difficult-to-follow internet world. Expand
Cholinesterase and carboxylesterase inhibitors as pharmacological agents
Literature data and authors’ own results on the role of serine hydrolases, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), as drug targets for treatment of neurodegenerative diseasesExpand
Monophosphoryl Lipid-A: A Promising Tool for Alzheimer's Disease Toll.
TLDR
It is argued that the TLR4 partial agonist MPL is a potentially safe and effective new pharmacological tool in AD. Expand
Ageing and Cognition.
TLDR
This chapter explores the notion of ARCD, with a perspective on potential key neurochemical pathways that can be targeted for future intervention and an increasing body of evidence implicating zinc homeostasis as a key player in learning and memory and also potentially ARCD. Expand
...
1
2
...

References

SHOWING 1-10 OF 2,181 REFERENCES
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
TLDR
This review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 19 categories according to their mechanism of action. Expand
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
TLDR
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 18 categories according to their mechanism(s) of action. Expand
Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
TLDR
In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified and enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. Expand
Drug therapies for cognitive impairment and dementia.
  • R. Howland
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2010
TLDR
Clinical trials in a diverse group of patients with age-related dementia or cognitive impairment demonstrated a significant benefit, but the methodology of these studies is poor, and long-term effects are unknown. Expand
Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease.
TLDR
These processes act to maintain the number and quality of synaptic connections in key brain regions and thus flavonoids have the potential to prevent the progression of neurodegenerative pathologies and to promote cognitive performance. Expand
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
TLDR
In a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD-related brain dysfunction, usable before clinical onset. Expand
Interactions of AChE with Aβ Aggregates in Alzheimer’s Brain: Therapeutic Relevance of IDN 5706
TLDR
It is concluded that early treatment with IDN 5706 decreases AChE–Aβ interaction and this effect might be of therapeutic interest in the treatment of AD. Expand
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
  • M. Youdim
  • Medicine
  • Current Alzheimer research
  • 2006
TLDR
The present ChEI anti AD drugs have limited symptomatic activity and devoid of neuroprotective property that is needed for disease modifying action. Expand
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
TLDR
Effects of davunetide on MCCB-rated cognition were not significant relative to placebo, and a significant beneficial effect was detected for the UPSA, providing guidance for continued clinical development in schizophrenia. Expand
Cerebrolysin in Alzheimer's disease.
TLDR
Although long-term studies are needed, the data available suggest that Cerebrolysin is effective as monotherapy and constitutes a promising option for combined therapy in Alzheimer's disease. Expand
...
1
2
3
4
5
...